Drug Profile

Idroxioleic acid - Neurofix Pharma

Alternative Names: 2-OHOA Neurofix Pharma; NFX-88

Latest Information Update: 26 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neurofix Pharma
Class Non-opioid analgesics; Nonsteroidal anti-inflammatories; Oleic acids; Small molecules
Mechanism of Action G protein-coupled receptor modulators; Phospholipase A1 inhibitors; Phospholipase A2 inhibitors; Prostaglandin-E synthase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 Jul 2022 Idroxioleic acid is still in phase II trials for Neuropathic pain in Spain (EudraCT2018-004792-13)
20 Jul 2022 Neurofix completes a phase-II trial in Neuropathic pain in Spain (NCT04148573; EudraCT2018-004792-13)
17 Jun 2019 Chemical structure information added

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com